Cellular bioenergetics after erythropoietin therapy in chronic renal failure
- PMID: 8621800
- PMCID: PMC507285
- DOI: 10.1172/JCI118647
Cellular bioenergetics after erythropoietin therapy in chronic renal failure
Abstract
After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O2 uptake (VO2 peak) as much as expected from the rise in hemoglobin concentration ([Hb]). In a companion study, we explain this phenomenon by the concurrent effects of fall in muscle blood flow after rHuEPO and abnormal capillary O2 conductance observed in CRF patients. The latter is likely associated with a poor muscle microcirculatory network and capillary-myofiber dissociation due to uremic myopathy. Herein, cellular bioenergetics and its relationships with muscle O2 transport, before and after rHuEPO therapy, were examined in eight CRF patients (27 +/- 7.3 [SD] yr) studied pre- and post-rHuEPO ([Hb] = 7.8 +/- 0.7 vs. 11.7 +/- 0.7 g x dl-1) during an incremental cycling exercise protocol. Eight healthy sedentary subjects (26 +/- 3.1 yr) served as controls. We hypothesize that uremic myopathy provokes a cytosolic dysfunction but mitochondrial oxidative capacity is not abnormal. 31P-nuclear magnetic resonance spectra (31P-MRS) from the vastus medialis were obtained throughout the exercise protocol consisting of periods of 2 min exercise (at 1.67 Hz) at increasing work-loads interspersed by resting periods of 2.5 min. On a different day, after an identical exercise protocol, arterial and femoral venous blood gas data were obtained together with simultaneous measurements of femoral venous blood flow (Qleg) to calculate O2 delivery (QO2leg) and O2 uptake (VO2leg). Baseline resting [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9 +/- 1.2 vs. 8.8 +/- 1.2, respectively), but it was significantly lower than in controls (10.9 +/- 1.5) (P = 0.01 each). At a given submaximal or peak VO2leg, no effects of rHuEPO were seen on cellular bioenergetics ([PCr]/[Pi] ratio, %[PCr] consumption halftime of [PCr] recovery after exercise), nor in intracellular pH (pHi). The post-rHuEPO bioenergetic status and pHi, at a given VO2leg, were below those observed in the control group. However, at a given pHi, no differences in 31P-MRS data were detected between post-rHuEPO and controls. After rHuEPO, at peak VO2, Qleg fell 20% (P < 0.04), limiting the change in QO2leg to 17%, a value that did not reach statistical significance. The corresponding O2 extraction ratio decreased from 73 +/- 4% to 68 +/- 8.2% (P < 0.03). These changes indicate that maximal O2 flow from microcirculation to mitochondria did not increase despite the 50% increase in [Hb] and explain how peak VO2leg and cellular bioenergetics (31P-MRS) did not change after rHuEPO. Differences in pHi, possibly due to lactate differences, between post-rHeEPO and controls appear to be a key factor in the abnormal muscle cell bioenergetics during exercise observed in CRF patients.
Similar articles
-
Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure.J Clin Invest. 1996 May 1;97(9):2092-100. doi: 10.1172/JCI118646. J Clin Invest. 1996. PMID: 8621799 Free PMC article.
-
Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.PLoS One. 2013 Jul 29;8(7):e69229. doi: 10.1371/journal.pone.0069229. Print 2013. PLoS One. 2013. PMID: 23922695 Free PMC article. Clinical Trial.
-
Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 1999 Jun;159(6):1726-34. doi: 10.1164/ajrccm.159.6.9804136. Am J Respir Crit Care Med. 1999. PMID: 10351910
-
The impact of recombinant human erythropoietin on exercise capacity in hemodialysis patients.Adv Ren Replace Ther. 1994 Apr;1(1):55-65. doi: 10.1016/s1073-4449(12)80022-7. Adv Ren Replace Ther. 1994. PMID: 7641089 Review.
-
Erythropoietin treatment for non-uremic patients: a personal view.Neth J Med. 1999 Jan;54(1):10-5. doi: 10.1016/s0300-2977(98)00124-7. Neth J Med. 1999. PMID: 10048290 Review.
Cited by
-
Chronic kidney disease induces a systemic microangiopathy, tissue hypoxia and dysfunctional angiogenesis.Sci Rep. 2018 Mar 28;8(1):5317. doi: 10.1038/s41598-018-23663-1. Sci Rep. 2018. PMID: 29593228 Free PMC article.
-
Uremic Myopathy and Mitochondrial Dysfunction in Kidney Disease.Int J Mol Sci. 2022 Nov 4;23(21):13515. doi: 10.3390/ijms232113515. Int J Mol Sci. 2022. PMID: 36362298 Free PMC article.
-
Review of Exercise Interventions to Improve Clinical Outcomes in Nondialysis CKD.Kidney Int Rep. 2024 Aug 2;9(11):3097-3115. doi: 10.1016/j.ekir.2024.07.032. eCollection 2024 Nov. Kidney Int Rep. 2024. PMID: 39534200 Free PMC article. Review.
-
Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease.JCI Insight. 2020 Mar 12;5(5):e133289. doi: 10.1172/jci.insight.133289. JCI Insight. 2020. PMID: 32161192 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous